You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

550 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Feb 2025
Guidelines and Advice
Status: Current
Version: N/A
Aug 2019
Drug
Other Name(s): Cabometyx®
May 2025
Guidelines and Advice
Guidelines and Advice
Aug 2019
Guidelines and Advice
Guidelines and Advice
Apr 2019
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Curative
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Sep 2019
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
May 2025

Pages